STOCK TITAN
  1. Home
  2. News
  3. ARVN

Arvinas, Inc - $ARVN STOCK NEWS

Welcome to our dedicated page for Arvinas news (Ticker: $ARVN), a resource for investors and traders seeking the latest updates and insights on Arvinas stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Arvinas's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Arvinas's position in the market.

News
Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update
Rhea-AI Summary

Arvinas reported strong Q1 2024 financial results along with key corporate updates. The company continued enrollment in multiple clinical studies of vepdegestrant in metastatic breast cancer, progressed ARV-102 for neurodegenerative diseases, and entered a lucrative transaction with Novartis. The strategic deal includes an exclusive license for ARV-766 and sale of the preclinical AR-V7 program, with significant upfront payment and potential milestone payments. Arvinas also made key appointments in its management team and remains on track with its Phase 3 clinical programs. Financially, the company's cash position is strong, with enough funding to support planned operations until 2027.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.42%
Tags
earnings
-
News
Arvinas to Present at Upcoming Investor Conferences
Rhea-AI Summary

Arvinas, Inc. (Nasdaq: ARVN) will be presenting at two investor conferences: the BofA Securities 2024 Healthcare Conference on May 14 and the UBS Spring Biotech Conferences on May 21. The company's Chief Medical Officer and Chief Business Officer will participate in various discussions and meetings.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.15%
Tags
conferences
-
News
Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer
Rhea-AI Summary
Arvinas, a clinical-stage biotechnology company focused on targeted protein degradation, has appointed Randy Teel, Ph.D., as Chief Business Officer. Dr. Teel, with almost 20 years of experience in the biopharmaceutical industry, has been instrumental in fostering relationships with investors and partners since Arvinas' IPO in 2018. His new role will involve leading corporate strategy, business development, investor relations, and communications while the company continues its search for a permanent CFO and Treasurer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.89%
Tags
management
News
Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer
Rhea-AI Summary
Arvinas (ARVN) enters into a strategic license agreement with Novartis for ARV-766 and preclinical AR-V7 program, receiving $150 million upfront and potential milestones of up to $1.01 billion. Novartis to lead worldwide clinical development for ARV-766, aiming to advance treatment for prostate cancer patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.44%
Tags
none
-
News
Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer
Rhea-AI Summary
Arvinas, Inc. appoints Dr. Noah Berkowitz as Chief Medical Officer, grants him an inducement package, and bids farewell to Dr. Ron Peck. Dr. Berkowitz brings extensive experience in clinical development and regulatory affairs from Bristol-Myers Squibb and Novartis, enhancing Arvinas' ongoing programs in oncology and neuroscience.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.09%
Tags
management
-
News
Arvinas to Participate in Upcoming Investor Conferences
Rhea-AI Summary
Arvinas, Inc. (ARVN) announces participation in three investor conferences where key executives will present and engage with investors. The company continues to showcase its advancements in targeted protein degradation drug development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.75%
Tags
conferences
News
Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Rhea-AI Summary
Arvinas, Inc. (ARVN) reports on clinical studies progress, financial results, and corporate updates. Vepdegestrant shows promising results in breast cancer treatment. ARV-766 demonstrates efficacy in mCRPC. The company received FDA Fast Track designation for vepdegestrant. Financially, Arvinas has a strong cash position, with $1,266.5 million in cash, cash equivalents, and marketable securities as of December 31, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.6%
Tags
earnings
-
News
Arvinas Announces Chief Financial Officer Transition
Rhea-AI Summary
Arvinas, Inc. announces the departure of CFO Sean Cassidy, with Randy Teel, Ph.D., stepping in as interim CFO. The company is conducting a search for a permanent replacement. Arvinas is a biotech firm specializing in targeted protein degradation drugs, with promising clinical trials and strong financial standing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.73%
Tags
none
-
News
Arvinas Announces First-in-Human Dosing of ARV-102, an Investigational PROTAC® Protein Degrader for Neurodegenerative Disease
Rhea-AI Summary
Arvinas, Inc. announced dosing the first subject in the Phase 1 trial of ARV-102, a novel oral PROTAC protein degrader targeting LRRK2 for neurodegenerative diseases. The drug has shown promising results in preclinical studies, crossing the blood-brain barrier and degrading LRRK2 by nearly 90%. The Phase 1 trial will assess safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy volunteers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.27%
Tags
none
News
Arvinas and Pfizer’s Vepdegestrant (ARV-471) Receives FDA Fast Track Designation for the Treatment of Patients with ER+/HER2- Metastatic Breast Cancer
Rhea-AI Summary
Arvinas, Inc. and Pfizer Inc. have announced that the FDA granted Fast Track designation for vepdegestrant (ARV-471) for monotherapy in the treatment of adults with estrogen receptor (ER) positive/human growth epidermal growth factor 2 (HER2) negative (ER+/HER2-) locally advanced or metastatic breast cancer previously treated with endocrine-based therapy. Vepdegestrant is a novel oral PROTAC® ER degrader being jointly developed by Arvinas and Pfizer, with the potential to harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. The Phase 3 VERITAC-2 clinical trial is evaluating vepdegestrant or fulvestrant in patients with locally advanced or metastatic ER+/HER2- breast cancer who have been previously treated with an endocrine-based therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.85%
Tags
clinical trial
Stock ARVN logo
Arvinas, Inc

Nasdaq:ARVN

ARVN Rankings

#1820 Ranked by Market Cap
#5164 Ranked by Stock Gains
N/A Ranked by Dividends

ARVN Stock Data

2.21B
55.84M
2.56%
97.28%
12.63%
Medicinal and Botanical Manufacturing
Manufacturing
Link
United States of America
NEW HAVEN

About ARVN

arvinas is a pharmaceutical company focused on developing new small molecules ‒ known as protacs (proteolysis targeting chimeras) ‒ aimed at degrading disease-causing cellular proteins via proteolysis. based on innovative research conducted at yale university by dr. craig crews, founder and chief scientific advisor, the company is translating natural protein degradation approaches into novel drugs for the treatment of cancer and other diseases. the proprietary protac-based drug paradigm induces protein degradation, rather than protein inhibition, using the ubiquitin proteasome system and offers the advantage of potentially targeting “undruggable” as well as “druggable” elements of the proteome. this greatly expands the ability to create drugs for many new, previously unapproachable targets. for more information, visit www.arvinas.com.